Company intelligence / Profile preview

Route 92 Medical

San Mateo, California, United Statesroute92medical.com ↗

Ownership: Private
Development stage: Commercial

Overview

Route 92 Medical’s HiPoint Reperfusion System demonstrated superior revascularization rates compared to conventional aspiration catheters in the SUMMIT MAX randomized controlled trial. The HiPoint system achieved a high first pass effect and successful delivery to the target occlusion in 89% of cases, with no significant difference in safety endpoints versus control. The company’s portfolio is FDA-cleared for some products and continues to expand through ongoing clinical studies.

Therapeutic areas: CardiovascularNeurology
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

Novo Holdings

Beyond the preview

Go deeper on Route 92 Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Route 92 Medical.

Explore the full profile